Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study
April 20, 2022 08:10 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study
March 31, 2022 08:10 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides
February 03, 2022 08:22 ET
|
Silo Pharma, Inc.
Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation Englewood Cliffs NJ, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a...
Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange
December 14, 2021 08:07 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced...
Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide
December 02, 2021 08:10 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the...
Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
November 18, 2021 09:45 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Reports Third Quarter Results and Operating Highlights
November 11, 2021 08:09 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
October 27, 2021 08:11 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma achieves milestone - Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology
October 07, 2021 08:11 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Advances Psychedelic Patent Portfolio
August 25, 2021 08:01 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...